Member Info for bunsenburner123

3.39p for £10k now lol

Wow there is literally no stock around

3.24p for £10k now

CAML & EST

Something big is going on in the background

£10k is now 3.08p

Bid and ask keep going up on no buys

Large background buy has just been put through the books clear to me

Book has completely flipped

Just picking up on this, bought some but still trying to compute. Definitely reading this right, half

Their cap in cash just won?

Have a funny feeling EST will breakout today

Pretty incredible that he’s on our board

Dr. Eric Verdin serves on the Scientific Advisory Board of Genflow Biosciences, contributing his extensive expertise in aging research to the company’s mission of developing gene therapies targeting the aging process. 

In addition to his role at Genflow, Dr. Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Aging, where he leads research on the molecular mechanisms of aging and age-related diseases. 

His involvement with Genflow Biosciences underscores the company’s commitment to leveraging leading scientific expertise in its pursuit of innovative treatments for age-related conditions.

If Genflow Biosciences demonstrates promising results in their longevity research, particularly in gene therapies targeting SIRT6 and aging-related diseases, their intellectual property (IP) portfolio could be highly valuable. Here’s how I’d estimate a potential valuation range for their IP:

1. Factors Affecting the Valuation of Genflow’s IP

The value of Genflow’s patents and IP would depend on:

✅ Clinical Success – Proof that their SIRT6-based gene therapy works in humans, particularly in trials like Werner syndrome.

✅ Patent Strength – Early, broad patents covering gene editing or therapy methods that competitors can’t easily work around.

✅ Market Size – Aging-related diseases (neurodegeneration, metabolic disorders) have a huge market, potentially hundreds of billions annually.

✅ Big Pharma Interest – Large biotech/pharma companies acquiring IP or licensing deals can drive up valuation.

✅ Regulatory Approvals – If aging becomes a recognized therapeutic target (like in the TAME trial for Metformin), the IP value increases dramatically.

2. Comparable Deals & Acquisitions in Longevity Biotech

Looking at recent biotech acquisitions & deals, companies with strong IP in longevity-related gene therapies have commanded significant valuations:

Company Technology Deal Type Valuation / Deal Size

Calico (Google spinout) Longevity R&D Private Investment $2.5 billion funding

Altos Labs (Jeff Bezos-backed) Cellular Reprogramming Private Investment $3 billion funding

Retro Biosciences Longevity Therapies Private Investment $180 million initial funding

Rejuvenate Bio Gene Therapy for Aging Partnership (with big pharma) Undisclosed (~$100M+ est.)

Unity Biotechnology Senolytics (Aging Therapy) IPO & Funding $300 million+

Genflow’s valuation would likely depend on their stage:

• Early-stage success (pre-clinical, strong IP) → $50M–$150M

• Proof of Concept in humans (early trials) → $200M–$500M

• Major breakthrough (late-stage trials, Big Pharma deals) → $1B+

3. Estimated IP Valuation for Genflow Biosciences

Based on their focus on gene therapy & longevity, I’d estimate their IP portfolio could be worth:

Stage Likely IP Value

Pre-clinical stage (now) $50M–$100M

Early human trials success $200M–$500M

Breakthrough longevity therapy $1B+

If their SIRT6-based gene therapy proves to be a viable longevity-enhancing treatment, big pharma or biotech investors could acquire them for over $1B in the long run.

Excellent article. Summarised below:

Key Takeaways on Genflow Biosciences from the Article

1. Genetic Links to Long Life

• Genflow Biosciences is developing gene therapies based on a rare mutation of the SIRT6 gene.

• This gene was found in centenarians (people over 100 years old) and is linked to longevity regulation in various species, including worms, fruit flies, and mice.

• SIRT6 encodes a protein from the sirtuin family, which plays a role in DNA repair, inflammation control, and metabolic regulation—all crucial factors in aging.

2. Challenges and Research Approach

• Aging is not yet recognized as a formal target for drug development, making clinical trials complex.

• Instead of directly targeting aging, Genflow plans to study aging through a specific disease model:

• They will conduct trials in patients with Werner syndrome, a disorder characterized by rapid aging symptoms.

• This allows them to test therapies for age-related processes while working within an established clinical framework.

• This strategy could later be expanded to broader anti-aging applications if their initial research is successful.

3. Potential Impact and Commercial Opportunities

• If their gene therapy proves effective, it could lead to new treatments for aging-related diseases.

• Early discoveries in longevity research, particularly genetic therapies like SIRT6-based interventions, could be valuable for intellectual property (IP) protection.

• Their work aligns with the broader longevity technology movement, which aims not just to extend lifespan but to increase healthspan—keeping people healthier for longer.

A Volcanogenic Massive Sulfide (VMS) deposit with 23 million tons at 1.2% Cu, recently defined by a JORC-compliant resource, could attract interest from large mining companies. The price they’d be willing to pay depends on several key factors:

1. How Mining Companies Value Deposits

Mining companies typically value projects based on Net Present Value (NPV), the Market Value per Pound of Copper, and comparable transactions.

A. Valuation Based on In-Ground Copper Value

• Your deposit contains 276,000 tons (or ~608 million lbs) of copper.

• Using a typical in-situ valuation metric, explorers often sell at:

• $0.01–$0.10 per lb Cu (early-stage deposits)

• $0.10–$0.30 per lb Cu (advanced-stage deposits with feasibility studies)

• $0.30–$1.00 per lb Cu (near-production or producing mines)

Since your deposit is at the JORC resource stage but lacks feasibility studies, it might trade at $0.05–$0.15 per lb Cu.





Estimated range: $30M – $91M USD.

B. Valuation Using EV/Resource Multiples

Junior mining companies typically trade at an Enterprise Value per Pound of Copper in the Ground between $0.02–$0.10/lb at this stage.

Applying this to your deposit:





So, a realistic price range might be $30M – $60M, unless there’s significant exploration upside.

C. Comparable Transactions (Recent VMS Project Sales)

Looking at recent VMS deposits sold in early stages, the range varies widely:

• Smaller VMS (5–10Mt): $10M–$40M

• Mid-size VMS (20–30Mt, like yours): $30M–$100M

• Larger, high-grade VMS (>50Mt): $100M+

Your JORC-defined 23Mt deposit with 1.2% Cu falls into the mid-tier. If it had a higher-grade zinc or gold component, it could command a premium.

2. Key Factors That Affect Sale Price

• Stage of Development: Pre-feasibility or feasibility studies significantly increase value.

• Metals Mix: If the deposit contains gold, zinc, silver, the price increases.

• Infrastructure & Location: Proximity to smelters, roads, and power lowers costs.

• Market Conditions: If copper prices surge, mining companies pay more.

• Exploration Potential: If there’s upside for more tonnage, the value rises.

3. Likely Sale Price Estimate

Based on these factors, a large mining company would likely offer $30M–$75M USD in a cash/equity deal

It’s not a leak

If you knew the assets they have you’d understand this should be valued around £50m

They have the backing of the worlds biggest mining company

They have one of the worlds largest VMS deposits

And a lot of other assets etc

It’s a sleeping giant and there’s no leak

Lol

Seriously though EST is class

Not the usual crap 💩

Oh shut up jungle this is not some pump and dump

This is a legitimately decent share and a great medium term opportunity

Take your short term nonsense elsewhere please

Brutal.

If they succeed this would be worth $10’s of billions

Good luck!

If he is describing genf’s technology or if genf’s technology achieves what he is describing then it’s likely that this share sees 100x as a minimum

A $1b company for sure so I doubt it but dream on big guy

I sense a leak of some kind which is naughty but seems to happen here

Have a funny feeling TRLS will do v well today being Friday and having tested 3p so many times this week